Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Proof of Principle Study of Pentarlandir™ UPPTA for the Treatment of Patients With Early COVID-19

NCT04911777 is registered in ClinicalTrials.gov with SyneuRx International (Taiwan) Corp as lead sponsor.

NCT NCT04911777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04911777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Proof of Principle Study of Pentarlandir™ UPPTA for the Treatment of Patients With Early COVID-19
Lead sponsor
SyneuRx International (Taiwan) Corp
Phase
Phase 2
Overall status
Unknown status
Start date
August 24, 2021
Completion date
March 31, 2022
Enrollment
90 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease 2019